The California-based company claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.

LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) continues to enroll its HARMONIC trial for LP-300 ...

brain tumors, and ALS (amyotrophic lateral sclerosis). But recent developments in medical physics have introduced ultrasound-activated microbubbles that temporarily open the BBB, allowing targeted ...

has been been found to have only a limited ability to penetrate into brain tumor tissue because of its P-gp activity. The inability of docetaxel to cross the BBB together with its ability to ...

“The systemic delivery of mRNA molecules to the central nervous system is challenging as they need to cross the blood-brain barrier (BBB) to reach into the brain. Here we design and synthesize ...

Here are five recent innovative bioprinting and bioink studies that are building synthetic biological structures.

It includes brain stem glioma ... therefore designs a dual mode nanoprobe for BBB crossing and in vivo visualization of typical GBM tumor boundaries. Radiotherapy is a key component of ...